Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth

Prostate cancer (PC) is driven by androgen receptor (AR) activity, a master regulator of prostate development and homeostasis. Frontline therapies for metastatic PC deprive the AR of the activating ligands testosterone (T) and dihydrotestosterone (DHT) by limiting their biosynthesis or blocking AR b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Nyquist, Michael D., Ang, Lisa S., Corella, Alexandra, Coleman, Ilsa M., Meers, Michael P., Christiani, Anthony J., Pierce, Cordell, Janssens, Derek H., Meade, Hannah E., Bose, Arnab, Brady, Lauren, Howard, Timothy, De Sarkar, Navonil, Frank, Sander B., Dumpit, Ruth F., Dalton, James T., Corey, Eva, Plymate, Stephen R., Haffner, Michael C., Mostaghel, Elahe A., Nelson, Peter S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2021
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8121509/
https://ncbi.nlm.nih.gov/pubmed/33998604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI146777
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados